Aniracetam
Synthetic racetam compound studied for cognitive symptoms in older adults with vascular impairment; benefits in healthy people are unproven.
Aniracetam
Synthetic racetam compound studied for cognitive symptoms in older adults with vascular impairment; benefits in healthy people are unproven.
Skip for healthy cognitive enhancement — evidence is limited to small studies in older clinical populations.
Aniracetam is a synthetic nootropic in the racetam family developed in the 1970s. It is approved for cognitive impairment in some countries, but not in the United States. Small clinical trials in elderly patients with cerebrovascular disorders suggest modest improvements in cognitive ratings and behavior. Animal studies indicate it modulates AMPA receptors and cholinergic signaling, but human mechanistic data are limited. Healthy adults seeking memory or focus enhancement have little controlled human evidence to support meaningful effects.
Proven Benefits
Protocol
Onset Time
Who Should Consider
How It Works
Aniracetam acts as a positive allosteric modulator of AMPA receptors, enhancing glutamatergic neurotransmission. It also appears to facilitate acetylcholine release in animal models, with downstream effects on dopamine and serotonin pathways. Human neurochemical data confirming these mechanisms are sparse.